Medigene AG (MDG1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medigene AG (MDG1) has a cash flow conversion efficiency ratio of -0.180x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.54 Million ≈ $-4.14 Million USD) by net assets (€19.66 Million ≈ $22.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medigene AG net asset quality index to measure how much of total assets are equity-financed.
Medigene AG - Cash Flow Conversion Efficiency Trend (2006–2023)
This chart illustrates how Medigene AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Medigene AG cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Medigene AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigene AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CAP-EX IRON ORE
F:X0V
|
-0.025x |
|
Biophytis S.A.
PA:ALBPS
|
0.472x |
|
PALATIN TECHS DL-01
F:PTN
|
N/A |
|
Chesterfield Resources PLC
LSE:CHF
|
-0.295x |
|
WINDELN.DE SE INH O.N.
F:WDL1
|
N/A |
|
Alliance Mining Corp
V:ALM
|
0.002x |
|
Plantarc Bio Ltd
TA:PLNT
|
-0.235x |
|
Jadestone Energy Inc
LSE:JSE
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Medigene AG (2006–2023)
The table below shows the annual cash flow conversion efficiency of Medigene AG from 2006 to 2023. For the full company profile with market capitalisation and key ratios, see Medigene AG (MDG1) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €21.07 Million ≈ $24.63 Million |
€-15.12 Million ≈ $-17.68 Million |
-0.718x | -321.90% |
| 2022-12-31 | €37.03 Million ≈ $43.29 Million |
€11.98 Million ≈ $14.00 Million |
0.323x | +234.79% |
| 2021-12-31 | €44.82 Million ≈ $52.39 Million |
€-10.75 Million ≈ $-12.57 Million |
-0.240x | +48.54% |
| 2020-12-31 | €53.15 Million ≈ $62.14 Million |
€-24.79 Million ≈ $-28.98 Million |
-0.466x | -132.33% |
| 2019-12-31 | €81.82 Million ≈ $95.66 Million |
€-16.42 Million ≈ $-19.20 Million |
-0.201x | -112.60% |
| 2018-12-31 | €107.42 Million ≈ $125.59 Million |
€-10.14 Million ≈ $-11.86 Million |
-0.094x | +60.98% |
| 2017-12-31 | €86.17 Million ≈ $100.74 Million |
€-20.85 Million ≈ $-24.37 Million |
-0.242x | -406.02% |
| 2016-12-31 | €78.59 Million ≈ $91.88 Million |
€-3.76 Million ≈ $-4.39 Million |
-0.048x | +59.43% |
| 2015-12-31 | €89.99 Million ≈ $105.21 Million |
€-10.61 Million ≈ $-12.40 Million |
-0.118x | +33.95% |
| 2014-12-31 | €49.07 Million ≈ $57.37 Million |
€-8.76 Million ≈ $-10.24 Million |
-0.178x | +47.14% |
| 2013-12-31 | €36.28 Million ≈ $42.41 Million |
€-12.25 Million ≈ $-14.32 Million |
-0.338x | -129.38% |
| 2012-12-31 | €44.22 Million ≈ $51.69 Million |
€-6.51 Million ≈ $-7.61 Million |
-0.147x | -202.77% |
| 2011-12-31 | €47.93 Million ≈ $56.04 Million |
€6.86 Million ≈ $8.02 Million |
0.143x | +151.20% |
| 2010-12-31 | €40.80 Million ≈ $47.70 Million |
€-11.41 Million ≈ $-13.34 Million |
-0.280x | +23.34% |
| 2009-12-31 | €51.87 Million ≈ $60.64 Million |
€-18.93 Million ≈ $-22.13 Million |
-0.365x | +13.45% |
| 2008-12-31 | €64.91 Million ≈ $75.88 Million |
€-27.36 Million ≈ $-31.99 Million |
-0.422x | -35.63% |
| 2007-12-31 | €103.09 Million ≈ $120.53 Million |
€-32.04 Million ≈ $-37.46 Million |
-0.311x | -2564.08% |
| 2006-12-31 | €108.51 Million ≈ $126.86 Million |
€-1.27 Million ≈ $-1.48 Million |
-0.012x | -- |
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more